# Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients

> **NCT02670109** · PHASE2 · UNKNOWN · sponsor: **Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran** · enrollment: 20 (estimated)

## Conditions studied

- Triple-Negative Invasive Breast Carcinoma
- Residual Tumor

## Interventions

- **DRUG:** Carmustine
- **DRUG:** Cyclophosphamide
- **DRUG:** Carboplatin
- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Busulfan

## Key facts

- **NCT ID:** NCT02670109
- **Lead sponsor:** Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-01
- **Primary completion:** 2020-11
- **Final completion:** 2021-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02670109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02670109, "Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02670109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*